Reduced levels of adiponectin, or hypoadiponectinemia, have been associated with adverse cardiovascular outcomes, diminished insulin sensitivity, and an elevated risk of Type 2 diabetes [35, 36], though whether adiponectin is causally related to outcomes, or rather a downstream marker of insulin action, remains debated [37, 38]. Here, ADIPOQ is linked to type 2 diabetes mellitus.